Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...

Atsena Therapeutics has raised $150 million in a round led by Bain Capital, a private investment firm based in Boston. The ...

Childhood-onset striatonigral degeneration is a rare genetic disorder that robs children of the ability to walk and speak by ...

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.

Three patients living with hypertrophic cardiomyopathy have had their disease classification downgraded following a single ...

Gene therapy, a technique that is revolutionizing the treatment of multiple genetic conditions, including eye and muscle diseases and blood disorders, requires efficient and specific delivery of the ...

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

Xcellbio announced today that it had granted bluebird bio, Inc., a commercial license and entered into a supply agreement for the use of Xcellbio’s proprietary cell manufacturing technology, AVATAR™, ...

British racing is testing thoroughbreds for gene doping after investing almost £2m into ground-breaking research – and the ...